XML 58 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
We generated net sales in the following geographic locations(1) (in millions):
Year Ended
December 31, 2023December 31, 2022December 31, 2021
U.S.$2,916.8 $2,870.0 $2,565.9 
Europe(2)
1,622.5 1,474.3 1,393.0 
All other countries(3)
116.3 107.3 179.8 
Total net sales$4,655.6 $4,451.6 $4,138.7 
(1)    The net sales by geography is derived from the location of the entity that sells to a third party.
(2)    Includes Ireland net sales of $40.8 million, $29.3 million, and $23.7 million for the years ended December 31, 2023, December 31, 2022, and December 31, 2021, respectively.
(3)    Includes revenue generated primarily in Australia and Canada during the year ended December 31, 2023. During the years ended December 31, 2022 and 2021, includes revenue generated primarily in Australia, Canada, and Mexico.
The following is a summary of our net sales by category (in millions):

Year Ended
December 31, 2023December 31, 2022December 31, 2021
CSCA(1)
Nutrition$563.2 $520.4 $401.9 
Upper Respiratory559.2 564.6 483.1 
Digestive Health505.3 495.5 475.1 
Pain and Sleep-Aids396.4 412.2 405.4 
Oral Care313.9 312.9 311.9 
Healthy Lifestyle311.7 288.9 295.0 
Skin Care196.2 187.8 183.7 
Women's Health46.9 45.2 38.2 
Vitamins, Minerals, and Supplements ("VMS")17.5 27.9 31.7 
Other CSCA(2)
52.0 70.5 67.1 
Total CSCA2,962.3 2,925.9 2,693.1 
CSCI
Skin Care372.5 334.6 324.0 
Upper Respiratory299.1 268.7 219.4 
Healthy Lifestyle225.7 209.7 227.6 
Pain and Sleep-Aids222.9 200.2 184.8 
VMS185.5 183.9 225.8 
Women's Health119.7 96.1 54.5 
Oral Care101.5 94.8 94.0 
Digestive Health41.0 35.5 25.6 
Other CSCI(3)
125.4 102.2 89.9 
Total CSCI1,693.3 1,525.7 1,445.6 
Total net sales$4,655.6 $4,451.6 $4,138.7 
(1)    Includes net sales from OTC contract manufacturing products.
(2)    Consists primarily of product sales and royalty income related to supply and distribution agreements and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
(3)    Consists primarily of our rare diseases business and other miscellaneous or otherwise uncategorized product lines, none of which is greater than 10% of the segment net sales.
Schedule of Contract with Customer Balances
The following table provides information about contract assets from contracts with customers (in millions):
Balance Sheet LocationDecember 31, 2023December 31, 2022
Short-term contract assetsPrepaid expenses and other current assets$28.5 $41.5